RAGE Cytosolic Tail Modulators for Ligand-Independent Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with RAGE activation, such as atherosclerosis and inflammatory disorders, are limited due to poor understanding of RAGE activation mechanisms and the inability to effectively target clinically important signaling pathways.
Innovation Solution
The discovery of RAGE ligand-independent activation by co-located GPCRs like AT1R and CCR2, which allows for modulation of RAGE signaling through the cytosolic tail without requiring RAGE ligands, providing a novel pathway for therapeutic intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional ligand-binding mechanisms are used to target RAGE, then RAGE signaling can be modulated, but the ability to selectively target clinically important signaling pathways is limited
Solution Approach 1:
The invention segments the RAGE receptor into two functional parts: the ectodomain (responsible for ligand binding) and the cytosolic tail (responsible for signaling). By developing modulators that specifically target the cytosolic tail domain rather than requiring ligand binding to the ectodomain, the invention enables selective modulation of RAGE signaling pathways independently of ligand presence, thereby improving adaptability to target clinically important pathways while simplifying the targeting mechanism
Solution Approach 2:
The invention introduces cytosolic tail domain modulators as intermediary molecules that directly interact with the intracellular portion of RAGE. These modulators act as mediators between the RAGE receptor and downstream signaling pathways, enabling selective control of signaling cascades without requiring traditional ligand-binding approaches. This intermediary mechanism allows for more precise and versatile targeting of clinically relevant pathways
2Loss of information
If RAGE ligands are used to activate RAGE, then RAGE signaling is activated, but the understanding of RAGE activation mechanisms remains poor
Solution Approach 1:
Instead of studying RAGE activation by working forward from ligand binding at the ectodomain, the invention inverts the approach by directly targeting the cytosolic tail domain where signaling initiation occurs. This reverse engineering approach allows researchers to directly observe and understand the activation mechanisms at the signaling interface, fundamentally improving understanding of how RAGE activation translates into cellular responses and enabling more reliable therapeutic interventions
3Adaptability or versatility
If co-located GPCRs are targeted to achieve RAGE ligand-independent activation, then novel therapeutic pathways are opened, but the complexity of the modulation mechanism increases
Solution Approach 1:
The invention merges the functional capabilities of co-located GPCRs with RAGE signaling by developing modulators that simultaneously address both receptor systems. By targeting the cytosolic tail domain that is shared or functionally connected between GPCRs and RAGE, the invention combines these pathways into a unified modulation mechanism, enabling novel therapeutic approaches while actually simplifying the overall modulation mechanism through domain-focused intervention
Data Source
AI summary
A method of screening candidate agents for their ability to modulate RAGE activity where such RAGE activity is induced by an active co-located GPCR, the method comprising the steps of: contacting a RAGE polypeptide with a GPCR polypeptide in the presence of a candidate agent where the GPCR polypeptide is constitutively active and/or is activated by addition of an agonist, partial agonist or allosteric modulator of that GPCR; and detecting whether the candidate agent is a modulator of RAGE ligand-independent activation of RAGE by activated co-located GPCR by detecting an effect indicative of modulation of RAGE activation by the presence of the candidate agent and/or by detecting RAGE-dependent signalling that is modulated by the presence of the candidate agent.